EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Echocardiographic Indices Compared with Galectin-3 and Pentraxin-3 in Stage C Heart Failure

Alexandru-Florinel Oancea, Paula Cristina Morariu, Maria Godun, Alexandru Jigoranu, Radu Stefan Miftode, Ovidiu Mitu, Paul Simion, Dragoș Traian Marcu, Amin Bazyani, Antoniu Octavian Petriș, Irina-Iuliana Costache-Enache, Mariana Floria

Medical Sciences · 2026-11-09 · 14 (7) · 765

DOI: 10.3390/medsci14070765 ↗
AbstractBibliografische Angaben

Abstract

Background/Objectives: We compared echocardiographic indices with galectin-3 and pentraxin-3 for discriminating established heart failure (HF). Methods: This exploratory cross-sectional secondary analysis included 131 coronary angiography patients: 69 with stage C HF and 62 without an established clinical HF syndrome. Patients with HF were clinically stable without symptoms at rest and were classified as New York Heart Association (NYHA) II or III at study evaluation. Tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP), the combined mitral Doppler index E/(Em × Sm), right ventricular systolic annular velocity, and both biomarkers were assessed using paired receiver operating characteristic comparisons and clinically adjusted logistic regression. Results: Among the measurements, TAPSE/PASP had the highest numerical area under the curve (AUC 0.753; 95% confidence interval 0.671–0.835) and outperformed galectin-3 (AUC 0.500; Holm-adjusted p = 0.0024). Its AUC difference from pentraxin-3 was nonsignificant. E/(Em × Sm) and pentraxin-3 had AUCs of 0.654 and 0.631. TAPSE/PASP had a nominal association in the clinical joint model, which was nonsignificant after LVEF adjustment (odds ratio 0.68 per standard deviation; 95% confidence interval 0.33–1.42). The pentraxin-3 HF-group contrast did not survive Holm correction (p = 0.0782). Conclusions: TAPSE/PASP discriminated established HF better than galectin-3 in this cohort. The separate pentraxin-3 association warrants further investigation of complementary inflammatory information. These exploratory findings, models, and derived thresholds require independent validation before clinical application.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →